16618-56-7

Basic information

• Product Name: 2-chloro-1,5-dimethyl-3-nitro-benzene
• Synonyms: 2-chloro-1,5-dimethyl-3-nitro-benzene
• CAS NO: 16618-56-7
• Molecular Weight: 185.61
• Mol File: 16618-56-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-chloro-1,5-dimethyl-3-nitro-benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-1,5-dimethyl-3-nitro-benzene(16618-56-7)
• EPA Substance Registry System: 2-chloro-1,5-dimethyl-3-nitro-benzene(16618-56-7)

Safety Data

• Hazardous Substances Data: 16618-56-7(Hazardous Substances Data)

Upstream product

• 95-66-9 2,4-dimethylchlorobenzene 
• 1635-84-3 2,4-Dimethyl-6-nitroanilin 

Downstream Products

• 108-69-0 3,5-dimethylaminoaniline 
• 1044871-11-5 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylquinazolin-4(3H)-one 
• 875241-52-4 2-amino-4,6-dimethyl benzamide 
• 860683-36-9 4,6-dimethyl-2-nitrobenzamide 
• 58579-99-0 2,4-dimethyl-6-nitro-benzonitrile 
• 35490-71-2 3,5-Dimethyl-2-(methylthio)anilin 
• 1222-09-9 2,4,4'-Trimethyl-6-nitro-diphenylsulfid 
• 35562-51-7 2-chloro-3,5-dimethyl-aniline 
• 35490-93-8 3,5-Dimethyl-2-(methylthio)-nitrobenzol 
• 859185-36-7 2-(2,4-dimethyl-6-nitro-anilino)-ethanol 

Relevant articles and documents

A 3,5-dimethyl aniline method for the preparation of

The invention discloses a preparation method of 3, 5-dimethylaniline. The preparation method is used for preparing the target product 3, 5-dimethylaniline through a reaction of chlorination, nitration and catalytic reductive dechlorination of a ring by taking m-xylene as a raw material. Compared with existing processes, the method disclosed by the invention is few in reaction step and simple in technological process. The yield of 3, 5-dimethylaniline based on m-xylene can reach over 75% of a theoretical amount. The cost of the 3, 5-dimethylaniline can be greatly lowered.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.